SUN-451 A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients with Cushing Syndrome (GRACE Study)

Relacorilant is a highly selective glucocorticoid receptor antagonist (GRA) that modulates the effects of excess cortisol while showing no affinity for progesterone, mineralocorticoid, androgen, or estrogen receptors. In a phase 2 study, treatment with relacorilant showed improvement in glycemic and...

Descripción completa

Detalles Bibliográficos
Autores principales: Auchus, Richard, Findling, James, Moraitis, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553349/
http://dx.doi.org/10.1210/js.2019-SUN-451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553349/
http://dx.doi.org/10.1210/js.2019-SUN-451

Ejemplares similares